Uterine cancer treatments
AssigneeImmatics Biotechnologies GmbH
InventorsAndrea Mahr, Toni Weinschenk, Colette Song, Oliver Schoor, Jens Fritsche, Harpreet Singh
Life of this patent
Estimating the term…
Loading patent…
AssigneeImmatics Biotechnologies GmbH
InventorsAndrea Mahr, Toni Weinschenk, Colette Song, Oliver Schoor, Jens Fritsche, Harpreet Singh
Estimating the term…
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
A method of treating uterine cancer in an HLA-A*02+ patient having a uterine cancer overexpressing an MSX1 polypeptide comprising the amino acid sequence of SEQ ID NO:
Dependencies are inferred from the claim text.